Jason Zemansky, an analyst from Bank of America Securities, maintained the Buy rating on Keros Therapeutics (KROS – Research Report). The associated price target remains the same with $33.00.
Don’t Miss TipRanks’ Half Year Sale
- Take advantage of TipRanks Premium for 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Jason Zemansky has given his Buy rating due to a combination of factors that highlight the potential value in Keros Therapeutics despite recent challenges. The company’s decision to explore strategic alternatives, such as a sale or further investment, indicates a proactive approach to enhancing shareholder value. Zemansky notes that the stock is trading significantly below its cash value, presenting an attractive opportunity for investors.
Additionally, the potential for near-term revenue from the partnership with Takeda for elritercept adds to the positive outlook. Despite the setback from the halted phase 2 TROPOS trial, Zemansky emphasizes the strength of the elritercept/Takeda partnership and the promising early-stage asset KER-065. The company’s strategic moves, including the adoption of a stockholder rights plan, further support the Buy rating by ensuring Keros maintains control over its future direction.
In another report released on April 9, Truist Financial also maintained a Buy rating on the stock with a $25.00 price target.
KROS’s price has also changed dramatically for the past six months – from $57.790 to $12.240, which is a -78.82% drop .